Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1

Regulatory Peptides

Volumn 109, Issue 1-3, 2002, Pages 155-165

  Balster, Douglas A ^a   O'Dorisio, M Sue ^b,c   Albers, Anne R ^a   Park, Sang K ^a   Qualman, Stephen J ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Differentiation; Neuroblastoma; Retinoic acid; Tumorigenicity; VIP; VPAC1

Indexed keywords

ADENYLATE CYCLASE; DNA; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CARCINOGENICITY; CELL CYCLE; CELL LINE; ENZYME KINETICS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NEURAL CREST; NEUROBLASTOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLOIDY; TUMOR GROWTH; UPREGULATION; WILD TYPE;

CELL CYCLE; CELL DIVISION; HUMANS; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; RECEPTORS, RETINOIC ACID; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION; VASOACTIVE INTESTINAL PEPTIDE;

MUS MUSCULUS;

EID: 0037111295     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(02)00199-4     Document Type: Article

References (73)

1. Abemayor E., Sidell N. Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. Environ. Health Perspect. 80:1989;3-15.
2. Ross R.A., Spengler B.A., Domenech C., Porubcin M., Rettig W.J., Biedler J.L. Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ. 6:1995;449-456.
3. Patterson P.H. Control of cell fate in a vertebrate neurogenic lineage. Cell. 62:1990;1035-1038.
4. Ono H., Kawa Y., Asano M., Ito M., Takano A., Kubota Y.et al. Development of melanocyte progenitors in murine steel mutant neural crest explants cultured with stem cell factor, endothelin-3, or TPA. Pigment Cell Res. 11:1998;291-298.
5. Cooper M.J., Hutchins G.M., Cohen P.S., Helman L.J., Mennie R.J., Israel M.A. Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts. Cell Growth Differ. 1:1990;149-159.
6. Pham T.D., Gershon M.D., Rothman T.P. Time of origin of neurons in the murine enteric nervous system: sequence in relation to phenotype. J. Comp. Neurol. 314:1991;789-798.
7. Doupe A.J., Patterson P.H., Landis S.C. Small intensely fluorescent cells in culture: role of glucocorticoids and growth factors in their development and interconversions with other neural crest derivatives. J. Neurosci. 5:1985;2143-2160.
8. Pence J.C., Shorter N.A. In vitro differentiation of human neuroblastoma cells caused by vasoactive intestinal peptide. Cancer Res. 50:1990;5177-5183.
9. Brenneman D.E., Nicol T., Warren D., Bowers L.M. Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J. Neurosci. Res. 25:1990;386-394.
10. O'Dorisio M.S., Fleshman D.J., Qualman S.J., O'Dorisio T.M. Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma. Regul. Pept. 37:1992;213-226.
11. Qualman S.J., O'Dorisio M.S., Fleshman D.J., Shimada H., O'Dorisio T.M. Neuroblastoma. Correlation of neuropeptide expression in tumor tissue with other prognostic factors. Cancer. 70:1992;2005-2012.
12. Cheung N.K., Kushner B.H., La Quaglia M.P., Kramer K., Ambros P., Ambros I.et al. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers. Eur. J. Cancer. 33:1997;2117-2120.
13. Kawakami T., Monobe Y., Monforte H., Woods W.G., Tuchman M., Lemieux B.et al. Pathology review of screening negative neuroblastomas: a report from the Quebec Neuroblastoma Screening Project. Cancer. 83:1998;575-581.
14. Kushner B.H., Cheung N.K. Neuroblastoma. Pediatr. Ann. 17:1988;269-284.
15. Stemple D.L., Anderson D.J. Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell. 71:1992;973-985.
16. Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res. 49:1989;219-225.
17. La Quaglia M.P., Manchester K.M. A comparative analysis of neuroblastic and substrate-adherent human neuroblastoma cell lines. J. Pediatr. Surg. 31:1996;315-318.
18. Sleight B.J., Soukup S., Ballard E.T., Parysek L.M. S-cells from a highly N-myc-amplified neuroblastoma are tumorigenic in nude mice. Anticancer Res. 13:1993;2031-2036.
19. Cornaglia-Ferraris P., Ponzoni M., Montaldo P., Mariottini G.L., Donti E., Di Martino D.et al. A new human highly tumorigenic neuroblastoma cell line with undetectable expression of N-myc. Pediatr. Res. 27:1990;1-6.
20. Breslow N., McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res. 31:1971;2098-2103.
21. Biedler J.L. Drug resistance: genotype versus phenotype - thirty-second G.H.A. Clowes Memorial Award Lecture. Cancer Res. 54:1994;666-678.
22. Rettig W.J., Spengler B.A., Chesa P.G., Old L.J., Biedler J.L. Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants. Cancer Res. 47:1987;1383-1389.
23. Hearing V.J., Ekel T.M. Mammalian tyrosinase. A comparison of tyrosine hydroxylation and melanin formation. Biochem. J. 157:1976;549-557.
24. Ross R.A., Biedler J.L. Presence and regulation of tyrosinase activity in human neuroblastoma cell variants in vitro. Cancer Res. 45:1985;1628-1632.
25. DeClerck Y.A., Bomann E.T., Spengler B.A., Biedler J.L. Differential collagen biosynthesis by human neuroblastoma cell variants. Cancer Res. 47:1987;6505-6510.
26. Mora J., Cheung N.K., Juan G., Illei P., Cheung I., Akram M.et al. Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res. 61:2001;6892-6898.
27. Arimura A., Said S.I. VIP, PACAP, and Related Peptides Second International Symposium. vol. 805:1996;The New York Academy of Sciences, New York.
28. Lelievre V., Pineau N., Du J., Wen C.H., Nguyen T., Janet T.et al. Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. A novel VIP-independent action of PHI via MAP kinase. J. Biol. Chem. 273:1998;19685-19690.
29. Rydel R.E., Greene L.A. cAMP analogs promote survival and neurite outgrowth in cultures of rat sympathetic and sensory neurons independently of nerve growth factor. Proc. Natl. Acad. Sci. U. S. A. 85:1988;1257-1261.
30. Pincus D.W., DiCicco-Bloom E.M., Black I.B. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature. 343:1990;564-567.
31. Pincus D.W., DiCicco-Bloom E., Black I.B. Trophic mechanisms regulate mitotic neuronal precursors: role of vasoactive intestinal peptide (VIP). Brain Res. 663:1994;51-60.
32. Waschek J.A. VIP and PACAP receptor-mediated actions on cell proliferation and survival. Ann. N.Y. Acad. Sci. 805:1996;290-300.
33. Waschek J.A., Muller J.M., Duan D.S., Sadee W. Retinoic acid enhances VIP receptor expression and responsiveness in human neuroblastoma cell, SH-SY5Y. FEBS Lett. 250:1989;611-614.
34. Goossens J.F., Manechez D., Pommery N., Formstecher P., Henichart J.P. VIP potentiates retinoic-acid effect on tissue transglutaminase activity in human neuroblastoma, the SK-N-SH cells. Neuropeptides. 24:1993;99-103.
35. Waschek J.A., Lelievre V., Bravo D.T., Nguyen T., Muller J.M. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines. Peptides. 18:1997;835-841.
36. Gourlet P., Vilardaga J.P., De Neef P., Waelbroeck M., Vandermeers A., Robberecht P. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides. 17:1996;825-829.
37. Gourlet P., Vandermeers A., Vandermeers-Piret M.C., De Neef P., Waelbroeck M., Robberecht P. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors. Biochim. Biophys. Acta. 1314:1996;267-273.
38. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281:1997;629-633.
39. Goetzl E.J., Pankhaniya R.R., Gaufo G.O., Mu Y., Xia M., Sreedharan S.P. Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses. Ann. N.Y. Acad. Sci. 840:1998;540-550.
40. Karacay B., O'Dorisio M.S., Summers M., Bruce J. Regulation of vasoactive intestinal peptide receptor expression in developing nervous systems. Ann. N.Y. Acad. Sci. 921:2000;165-174.
41. Reubi J.C. In vitro identification of VIP receptors in human tumors: potential clinical implications. Ann. N.Y. Acad. Sci. 805:1996;753-759.
42. Vertongen P., d'Haens J., Michotte A., Velkeniers B., Van Rampelbergh J., Svoboda M.et al. Expression of pituitary adenylate cyclase activating polypeptide and receptors in human brain tumors. Peptides. 16(4):1995;713-719. [Ref. Type: Abstract].
43. Pence J.C., Shorter N.A. Autoregulation of neuroblastoma growth by vasoactive intestinal peptide. J. Pediatr. Surg. 27:1992;935-943.
44. Melino G., Thiele C.J., Knight R.A., Piacentini M. Retinoids and the control of growth/death decisions in human neuroblastoma cell lines. J. Neuro-Oncol. 31:1997;65-83.
45. Melino G., Draoui M., Bellincampi L., Bernassola F., Bernardini S., Piacentini M.et al. Retinoic acid receptors alpha and gamma mediate the induction of "tissue" transglutaminase activity and apoptosis in human neuroblastoma cells. Exp. Cell Res. 235:1997;55-61.
46. Melino G., Piacentini M. 'Tissue' transglutaminase in cell death: a downstream or a multifunctional upstream effector? FEBS Lett. 430:1998;59-63.
47. Oliverio S., Amendola A., Di Sano F., Farrace M.G., Fesus L., Nemes Z.et al. Tissue transglutaminase-dependent posttranslational modification of the retinoblastoma gene product in promonocytic cells undergoing apoptosis. Mol. Cell. Biol. 17:1997;6040-6048.
48. Melino G., Annicchiarico-Petruzzelli M., Piredda L., Candi E., Gentile V., Davies P.J.et al. Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol. Cell. Biol. 14:1994;6584-6596.
49. Boix J., Fibla J., Yuste V., Piulats J.M., Llecha N., Comella J.X. Serum deprivation and protein synthesis inhibition induce two different apoptotic processes in N18 neuroblastoma cells. Exp. Cell Res. 238:1998;422-429.
50. Mejia M.C., Navarro S., Pellin A., Castel V., Llombart-Bosch A. Study of bcl-2 protein expression and the apoptosis phenomenon in neuroblastoma. Anticancer Res. 18:1998;801-806.
51. Reed J.C. Double identity for proteins of the Bcl-2 family. Nature. 387:1997;773-776.
52. Chen M.K., Strande L., Kain M., Whalen T.V., Doolin E.J. Induction of apoptosis in a neuroblastoma and hepatocyte coculture model. J. Surg. Res. 78:1998;123-130.
53. Biedler J.L., Helson L., Spengler B.A. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 33:1973;2643-2652.
54. Tumilowicz J.J., Nichols W.W., Cholon J.J., Greene A.E. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res. 30:1970;2110-2118.
55. Bian X., McAllister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G.et al. NF-κB activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J. Biol. Chem. 276:2001;48921-48929.
56. Fruhwald M.C., O'Dorisio M.S., Fleitz J., Pietsch T., Reubi J.C. Vasoactive intestinal peptide (VIP) and VIP receptors: gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood. Int. J. Cancer. 81:1999;165-173.
57. Lara-Marquez M., O'Dorisio M., O'Dorisio T., Shah M., Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 166:2001;2522-2530.
58. Lehmann S., Paul C., Torma H. Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells. Clin. Cancer Res. 7:2001;367-373.
59. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: a Laboratory Manual. 2nd Ed. 1989;Cold Spring Harbor Laboratory Press, New York.
60. O'Dorisio M.S., Hermina N.S., O'Dorisio T.M., Balcerzak S.P. Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase. J. Immunol. 127:1981;2551-2554.
61. O'Dorisio M.S., Vandenbark G.R., LoBuglio A.F. Human monocyte killing of Staphylococcus aureus: modulation by agonists of cyclic adenosine 3′,5′-monophosphate and cyclic guanosine 3′,5′-monophosphate. Infect. Immun. 26:1979;604-610.
62. Darzynkiewicz Z., Juan G. DNA content measurement for DNA ploidy and cell cycle analysis. Curr. Protoc. Cytom. Unit 7.5:1997;7.5.1-7.5.24.
63. Cooper M.J., Hutchins G.M., Cohen P.S., Helman L.J., Israel M.A. Neuroblastoma cell lines mimic chromaffin neuroblast maturation. Prog. Clin. Biol. Res. 366:1991;343-350.
64. Kashimoto K., Nagano Y., Suitani Y., Hamanaka K., Mizumoto T., Tomizaki K.et al. Structure-activity relationship studies of PACAP-27 and VIP analogues. Ann. N.Y. Acad. Sci. 805:1996;505-510.
65. Vertongen P., Devalck C., Sariban E., De Laet M.H., Martelli H., Paraf F.et al. Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas. J. Cell. Physiol. 167:1996;36-46.
66. Vertongen P., De Clerck P., Fournet J.C., Martelli H., Helardot P., Devalck C.et al. Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues. Neuropeptides. 31:1997;409-413.
67. Anderson D.J., Groves A., Lo L., Ma Q., Rao M., Shah N.M.et al. Cell lineage determination and the control of neuronal identity in the neural crest. Cold Spring Harbor Symp. Quant. Biol. 62:1997;493-504.
68. Rao M.S., Anderson D.J. Immortalization and controlled in vitro differentiation of murine multipotent neural crest stem cells. J. Neurobiol. 32:1997;722-746.
69. Gill R.M., Slack R., Kiess M., Hamel P.A. Regulation of expression and activity of distinct pRB, E2F, D-type cyclin, and CKI family members during terminal differentiation of P19 cells. Exp. Cell Res. 244:1998;157-170.
70. Juan G., Li X., Darzynkiewicz Z. Phosphorylation of retinoblastoma protein assayed in individual HL-60 cells during their proliferation and differentiation. Exp. Cell Res. 244:1998;83-92.
71. Brodeur G.M. Neuroblastoma - clinical applications of molecular parameters. Brain Pathol. 1:1990;47-54.
72. Bourhis J., Benard J., DeVathaire F., Wilson G.D., Hartmann O., Terrier-Lacombe M.J.et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Prog. Clin. Biol. Res. 366:1991;107-113.
73. Look A.T., Hayes F.A., Nitschke R., McWilliams N.B., Green A.A. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N. Engl. J. Med. 311:1984;231-235.